• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
Harvard Law School Bankruptcy Roundtable

Harvard Law School Bankruptcy Roundtable

  • Blog
  • About Us
  • Coverage-in-Depth
    • Crypto-Bankruptcy
    • Purdue Pharma Bankruptcy
    • Texas Two-Step and the Future of Mass Tort Bankruptcy
  • Subscribe
  • Show Search
Hide Search

[Purdue Pharma Bankruptcy Series] Senate Judiciary Committee Subcommittee Hearing on “Evading Accountability: Corporate Manipulation of Chapter 11 Bankruptcy”: A Recap

Editor’s Note: On August 10, 2023, the Supreme Court of the United States agreed to hear the appeal of the bankruptcy of Purdue Pharma. In its grant of certiorari, the Supreme Court asked the parties to brief and argue “[w]hether the Bankruptcy Code authorizes a court to approve, as part of a plan of reorganization under Chapter 11 of the Bankruptcy Code, a release that extinguishes claims held by nondebtors against nondebtor third parties, without the claimants’ consent.” Following on the BRT’s previous coverage of recent developments in mass tort bankruptcies, the next few posts will address Purdue’s bankruptcy in particular and the issues raised by third-party releases and mass tort bankruptcies more generally.

For some prior coverage on the BRT regarding Purdue Pharma’s bankruptcy, please see articles here (by Martin J. Bienenstock & Daniel S. Desatnik and Jared Mayer) here (by Jonathan Lipson, Adam Levitin, and Stephen Lubben), here (by William Organek), here (by Marshall Huebner and Marc Tobak), and here (by Jonathan Lipson).

***

By Lauren Pansegrau and Jessie (Ziyu) Lin (Harvard Law School)


Lauren Pansegrau and Jessie (Ziyu) Lin

On September 19, 2023, the U.S. Senate Judiciary Committee convened a significant hearing to examine the use of Chapter 11 bankruptcy by corporations, with a particular focus on Johnson & Johnson (J&J) and its “Texas Two-Step” strategy to address mass tort liabilities related to its baby powder products. The hearing featured several key witnesses, including Mr. Erik Haas, J&J’s Worldwide Vice President of Litigation, legal experts Mr. Stephen Hessler, Professor Melissa Jacoby, and Professor Samir D. Parikh, and a mesothelioma victim’s family representative, Ms. Lori Knapp.

The debate revolved around whether bankruptcy is an appropriate avenue for resolving mass tort liabilities or if it is being misused to shield corporate wrongdoers from accountability. Some witnesses and committee members expressed concern about corporate maneuvers, such as divisive mergers, which may allow companies to enjoy the benefits of bankruptcy without its costs. They emphasized that bankruptcy was not intended to serve as an alternative justice system for tort claims, calling for additional safeguards if bankruptcy continues to be used for this purpose. Others argued that bankruptcy provides a more efficient and equitable way to compensate victims in mass tort cases, compared to lengthy class action or multi-district litigation processes. The hearing focused particularly on J&J’s Texas Two-Step strategy, where the company restructured its subsidiary to separate talc liabilities from other assets, followed by a bankruptcy filing. Some senators questioned the legitimacy of this approach, given J&J’s significant financial strength, and inquired whether Congress can implement federal laws to establish a minimum standard for the use of divisive merger in mass tort cases.

Another topic discussed was nonconsensual third-party releases, which involve extinguishing claims held by third parties without their consent. There was a split of opinions among witnesses: some advocated for individual claimants to have the option to consent to having their rights altered or opt out, while others maintained that the Bankruptcy Code does provide for nonconsensual third-party releases and emphasized that such releases are essential to resolving cases and improving tort victim recoveries. In addition, in the hearing, senators also emphasized the need for improved protection of employee claims and administrative priority claims in bankruptcy proceedings.

Click here to read the full article.

Written by:
Editor
Published on:
September 26, 2023
Thoughts:
No comments yet

Categories: Bankruptcy, Bankruptcy Reform, Chapter 11, Purdue Pharma Bankruptcy, Texas Two-Step, Third-Party ReleasesTags: Jessie Lin, Lauren Pansegrau, syndicated

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Categories

Recent Posts

  • Chapter 15 Case Demonstrates Its Effectiveness as an Expedient Judicial Solution for Singaporean Insolvencies in the United States May 13, 2025
  • Do Rights Offerings Reduce Bargaining Complexity in Chapter 11? May 6, 2025
  • Rockville Centre Case Offers a Framework for Settling Mass Tort Bankruptcy Claims Post-Purdue April 29, 2025

View by Subject Matter

363 sales Anthony Casey Bankruptcy Bankruptcy administration Bankruptcy Courts Bankruptcy Reform Chapter 11 Chapter 15 Claims Trading Cleary Gottlieb Comparative Law Corporate Governance COVID-19 cramdown David Skeel Derivatives DIP Financing Empirical FIBA Financial Crisis fraudulent transfer Jared A. Ellias Jevic Johnson & Johnson Jones Day Mark G. Douglas Mark Roe plan confirmation Priority Purdue Pharma Purdue Pharma bankruptcy restructuring Safe Harbors Schulte Roth & Zabel Sovereign Debt SPOE Stephen Lubben Structured Dismissals Supreme Court syndicated Texas Two-Step Trust Indenture Act Valuation Weil Gotshal Workouts

Footer

Harvard Law School Bankruptcy Roundtable

1563 Massachusetts Ave,
Cambridge, MA 02138
Accessibility | Digital Accessibility | Harvard Law School

Copyright © 2023 The President and Fellows of Harvard College

Copyright © 2025 · Navigation Pro on Genesis Framework · WordPress · Log in